A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting

Background: Therapy resistance remains a serious dilemma in metastatic castration-resistant prostate cancer (mCRPC) with primary or secondary resistance frequently occurring against any given therapy. Available prognostic models for Abiraterone Acetate (AA) are specifically designed for either pre-...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Boegemann, Martin, Schlack, Katrin, Früchtenicht, Lena, Steinestel, Julie, Schrader, Andres Jan, Wennmann, Yvonne, Krabbe, Laura-Maria, Eminaga, Okyaz
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2019
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6707939/
https://ncbi.nlm.nih.gov/pubmed/31489117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27133
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky